Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.80 (+1.14%) Hang Seng
18,079.61 -150.59 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,273.66 -2,072.62 (-2.99%) CMC Crypto 200
1,416.71 -11.86 (-0.83%)
GILD Jan 2025 32.500 call
| Previous close | 43.45 |
| Open | 43.45 |
| Bid | 34.50 |
| Ask | 37.20 |
| Strike | 32.50 |
| Expiry date | 2025-01-17 |
| Day's range | 43.45 - 43.65 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksGilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.
Business WireEVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
FOSTER CITY, Calif., May 31, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract #LBA8500) today (2:45-5:45pm CT) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The results were also published simultaneously in the Journal of Clinical Oncology. The company previously announced that the study did not meet the primary endpoint of overall survival (OS) in previou
Business WireGilead Provides Update on Phase 3 TROPiCS-04 Study
FOSTER CITY, Calif., May 30, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC). The TROPiCS-04 study evaluated Trodelvy® (sacituzumab govitecan-hziy; SG) vs. single-agent chemotherapy (treatment of physicians’ choice, TPC) in patients with mUC who have previously received platinum-containing chemotherapy and anti-PD-(L)1 therapy.
